My watch list
my.chemeurope.com  
Login  

Principal Scientist Phage Technology (m/f)

Advertisement No. CK/10567
More about Amgen
  • News

    Amgen Completes Acquisition of Alantos

    Amgen announced the completion of its acquisition of Alantos, a private company developing drugs for the treatment of diabetes and inflammatory diseases. The transaction provides Amgen with Alantos's DPP-IV inhibitor in clinical development (Phase 2a) for the treatment of type II diabetes a ... more

    Amgen Dedicates Cambridge, Mass. Research Center Focusing On Small Molecule Drug Discovery

    Amgen (NASDAQ:AMGN) today dedicated its 285,000 square foot research facility in the heart of the Cambridge-Boston biotechnology corridor. Amgen's work in the state-of-the-art, eight-story laboratory and research facility will focus on researching and discovering small molecule drug candi ... more

    FDA Approves Amgen's Aranesp™ For Anemia

    Amgen (Nasdaq:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AranespÔ (darbepoetin alfa) for the treatment of anemia associated with chronic renal failure. Aranesp requires fewer injections than the existing treatment, Epoetin alfa, which is marketed u ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE